The present and future of bispecific antibodies for cancer therapy

C Klein, U Brinkmann, JM Reichert… - Nature reviews Drug …, 2024‏ - nature.com
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Humanized mouse models for immuno-oncology research

J Chuprin, H Buettner, MO Seedhom… - Nature Reviews …, 2023‏ - nature.com
Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Challenges and new technologies in adoptive cell therapy

P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023‏ - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

The use of RNA-based treatments in the field of cancer immunotherapy

M Chehelgerdi, M Chehelgerdi - Molecular Cancer, 2023‏ - Springer
Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023‏ - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Engineering CAR-T cells for next-generation cancer therapy

M Hong, JD Clubb, YY Chen - Cancer cell, 2020‏ - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020‏ - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

N Albinger, J Hartmann, E Ullrich - Gene therapy, 2021‏ - nature.com
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …

Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

L Lu, M **e, B Yang, W Zhao, J Cao - Science Advances, 2024‏ - science.org
Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …

Programmable synthetic receptors: the next-generation of cell and gene therapies

F Teng, T Cui, L Zhou, Q Gao, Q Zhou… - Signal Transduction and …, 2024‏ - nature.com
Cell and gene therapies hold tremendous promise for treating a range of difficult-to-treat
diseases. However, concerns over the safety and efficacy require to be further addressed in …